Drugs / Cefamezine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06814223 Comparator | Oct 2024 → Dec 2027 expected | prosthesis-related infectious disease | Western Galilee Hospital-Nahariya | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cefamezine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06814223 ↗ |
| Route | Intravenous | “Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously.” NCT06814223 ↗ |